At a glance
- Originator Penn State College of Medicine
- Developer SuperGen
- Class Antihyperglycaemics; Antihyperlipidaemics; Antihypertensives; Pyrazines; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic complications; Hyperlipidaemia; Type 2 diabetes mellitus
Most Recent Events
- 16 Nov 2006 Pyrazinoguanidine is still available for licensing (http://www.supergen.com)
- 16 Mar 2005 Phase-II clinical trials in Diabetes mellitus in USA (PO)
- 03 Feb 2004 Pyrazinoguanidine is still available for licensing (http://www.supergen.com)